Found 15 articles for: "Scarring"
Persistent Alopecic Patches Following Dutasteride Mesotherapy for Female Androgenetic Alopecia: A Case Series
March 2026 | Volume 25 | Issue 3 | Original Article | 951 | Copyright © March 2026
Background: Androgenetic alopecia (AGA) is the most common cause of hair loss. To minimize systemic adverse effects of 5-alpha-reductase inhibitors, dutasteride mesotherapy has g...
Read MorePatient Perspectives and Attitudes Toward the Diagnostic Process for Central Centrifugal Cicatricial Alopecia
March 2026 | Volume 25 | Issue 3 | Features | 282 | Copyright © March 2026
A Decade of Hair Prosthetic Injuries: A Review of United States Emergency Department Cases (2013-2022)
March 2026 | Volume 25 | Issue 3 | Features | 277 | Copyright © March 2026
Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics
March 2026 | Volume 25 | Issue 3 | Case Reports | 275 | Copyright © March 2026
Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory disorder of the scalp that manifests as inflamed nodules and abscesses, with subsequent patchy, scarring hair loss. While its ex...
Read MoreScar Wars: A Review of Topical Scar Therapies
December 2025 | Volume 24 | Issue 12 | Features | 1265 | Copyright © December 2025
Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% for Acne: Results From A 6-Month Open-Label Study
May 2025 | Volume 24 | Issue 5 | Original Article | 516 | Copyright © May 2025
Background: Treatment of acne may require many months of treatment before maximal benefits are observed, and acne sequelae (eg, scarring, dyspigmentation) can persist long a...
Read MoreAlopecia as an Adverse Event of Immune Checkpoint Inhibitor Therapies: Clinical Evidence and Outcomes
March 2025 | Volume 24 | Issue 3 | Original Article | 255 | Copyright © March 2025
Immunotherapy utilizing immune checkpoint inhibitors (ICIs) such as PD-1, PD-L1, and CTLA-4 inhibitors has revolutionized cancer therapy by enhancing T cell recognition and attack against cancer ...
Read MoreThe Frequency of Non-Scarring Alopecia in Autoimmune Connective Tissue Diseases
March 2025 | Volume 24 | Issue 3 | Original Article | 246 | Copyright © March 2025
Background: Autoimmune connective tissue diseases (ACTDs) are relatively rare systemic diseases featured by immune dysregulation and often have prominent cutaneous manifestations...
Read MoreDifferentiating and Managing Cutaneous Lupus Erythematosus-Associated Alopecia and Patchy Alopecia Areata: Therapeutic Insights From Case Studies
March 2025 | Volume 24 | Issue 3 | Case Reports | 324 | Copyright © March 2025
Cutaneous lupus erythematosus (CLE) is an autoimmune disease with diverse clinical manifestations, including patchy hair lossresembling alopecia areata (AA). This report describes tw...
Read MoreA Review of Management Strategies for Erosive Pustular Dermatosis of the Scalp
February 2025 | Volume 24 | Issue 2 | Features | 217 | Copyright © February 2025
Utility of Adding Platelet-Rich Plasma to Microneedling vs Microneedling Alone in the Treatment of Acne Scarring
January 2025 | Volume 24 | Issue 1 | Original Article | 41 | Copyright © January 2025
Acne vulgaris is one of the most common skin diseases worldwide and affects a large population of patients. Post-acne scarring can pose a significant psychosocial burden on patients of all ages; ...
Read MoreLaser and Energy Treatments for Acne Scarring: A Review of Clinical Trials
December 2024 | Volume 23 | Issue 12 | Original Article | 1058 | Copyright © December 2024
Background: Acne scarring can have a detrimental impact on quality of life, making early and effective treatment essential. Lasers and energy-based treatment are the preferred tr...
Read MorePlatelet Rich Plasma for the Treatment of Scarring Alopecia Due to Discoid Lupus Erythematosus
March 2022 | Volume 21 | Issue 3 | Case Reports | 309 | Copyright © March 2022
Platelet-rich plasma (PRP) is an autologous concentration of plasma from a patient’s blood containing platelets up to 7 times higher than normal plasma. Originally indicated to improve connectiv...
Read MoreBotulinum Neurotoxin Type A as an Adjuvant to Reduce Scarring After Dermatological Surgery
June 2021 | Volume 20 | Issue 6 | Original Article | 677 | Copyright © June 2021
Botulinum neurotoxin type A (BoNTA) is thought to have biological effects beyond muscle paralysis, including direct effects on wound healing. This provides a potential rationale for adjuvant intraderm...
Read MoreCharacterization and Clinical Significance of Non-Scarring Alopecia in Systemic Lupus Erythematosus
May 2021 | Volume 20 | Issue 5 | Editorials | 584 | Copyright © May 2021
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
